Drug intelligence / Profile preview

Wenpi Qingwei Granules

Development stage: Phase 3
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Wenpi Qingwei Granules is a drug being investigated for the treatment of Nonerosive Reflux Disease. It is formulated as granules, suggesting an oral route of administration, and is likely an herbal medicine, possibly a Traditional Chinese Medicine formulation, given the developing institutions. The specific mechanism of action is not provided in the available context.

Other names: 温脾清胃颗粒

Targets

MLNR (Human motilin receptor)

Beyond the preview

Go deeper on Wenpi Qingwei Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wenpi Qingwei Granules.

Explore the full profile